Trials / Completed
CompletedNCT02816099
Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients
Study of the Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesterol Ester Transfer Protein (CETP) in Type-1 Diabetes Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 206 (actual)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In type-1 diabetes patients, bad cholesterol tends to accumulate because apoC1 function is slowed down. ApoC1 is a protein whose role is to diminish the activity of CETP, another protein that regulates cholesterol transfer in the body. The aim of this study is to determine whether it is possible to correct apoC1 function by improving glycaemic balance. 240 persons will be recruited in this study and allocated to one of two groups: * 160 Type-1 diabetes patients with uncontrolled diabetes: * 4 additional blood samples will be taken at the time of the systematic biological examination at inclusion and then again 3 months later. * 80 control subjects with normal lipids and normal glycaemia balance will be included in the study following the results of the biological assays. * 4 blood samples will be taken at the time of inclusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Prise de sang |
Timeline
- Start date
- 2014-11-20
- Primary completion
- 2022-11-14
- Completion
- 2022-11-14
- First posted
- 2016-06-28
- Last updated
- 2026-02-06
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02816099. Inclusion in this directory is not an endorsement.